Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21330037 | 1.00 | CDK2 (0.32) | CDK2CYP11B1CYP11B2 | |
| SCHEMBL21329911 | 1.00 | CDK2 (0.32) | CDK2CYP11B1CYP11B2 | |
| SCHEMBL21392028 | 0.71 | CYP2C19 (0.36) | — | |
| SCHEMBL31080759 | 0.71 | POLQ (0.36) | — | |
| SCHEMBL21329678 | 0.70 | LRRK2 (0.32) | CDK2 | |
| SCHEMBL26685345 | 0.66 | CNR2 (0.34) | — | |
| SCHEMBL31543520 | 0.65 | ALOX5 (0.31) | — | |
| SCHEMBL28997683 | 0.64 | PDE2A (0.32) | — | |
| SCHEMBL21348808 | 0.62 | ALOX5 (0.37) | — | |
| SCHEMBL4303555 | 0.62 | CDK2 (0.41) | CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255423-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
| WO-2019178079-A9 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | ABBVIE INC. (US) | 2019-12-12 | — | — | WO | disclosed |
| WO-2019178079-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | ABBVIE INC. (US) | 2019-09-19 | — | — | WO | disclosed |
| EP-3539966-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | AbbVie Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190276450-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | ABBVIE INC. | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276450-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | PTK2B, ABL1, BTK | CDK2 126/4885CYP11B1 2194/4885CYP11B2 1873/4885 |
| US-20200255423-A1 | INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING | PTK2B, ABL1, BTK | CDK2 126/4885CYP11B1 2194/4885CYP11B2 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.